Histologic evidence of a radiosensitizing effect of Taxol in patients with astrocytomas

Tarek Wehbe, Michael Glantz, Hak Choy, Lisa Glantz, Selina Cortez, Wallace Akerley, Pam Mills, Bernard Cole

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The new anticancer agent Taxol appears to potentiate the effects of radiation on brain tumor cell lines in vitro and was recently evaluated by our group as a radiosensitizer in a phase I study for primary brain tumors. In that study, we administered Taxol as a three-hour IV infusion repeated every week for six weeks and gave daily cranial irradiation concurrently for a total of 6000 rads. We reviewed the charts of the 60 patients who participated in the study, and identified twelve patients who underwent a second surgery after treatment because of progressive symptoms and an enlarging intracranial mass on MRI. Pathologically, each patient showed prominent radionecrosis, and other evidence of accelerated radiation changes (confluent areas of coagulative necrosis, bizarre nuclei, marked thickening and fibrinoid changes in multiple blood vessels). These changes were noted many weeks earlier than would be expected after radiation therapy alone and were independent of age, and tumor histology. We postulate that the accelerated radiation changes may be due to the radiation sensitizing effects of Taxol. We also noted a change of the pattern of tumor recurrence, compared to historic reports, and a dose-necrosis relationship where the resected tumor is formed completely of necrotic tissue in patients who received 150 mg/m2 or higher dose of Taxol. These observations may be of significance for future study design.

Original languageEnglish (US)
Pages (from-to)245-251
Number of pages7
JournalJournal of neuro-oncology
Volume39
Issue number3
DOIs
StatePublished - Nov 3 1998

Fingerprint

Radiation-Sensitizing Agents
Astrocytoma
Paclitaxel
Brain Neoplasms
Necrosis
Radiation
Cranial Irradiation
Neoplasms
Radiation Effects
Tumor Cell Line
Antineoplastic Agents
Blood Vessels
Histology
Radiotherapy
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Wehbe, Tarek ; Glantz, Michael ; Choy, Hak ; Glantz, Lisa ; Cortez, Selina ; Akerley, Wallace ; Mills, Pam ; Cole, Bernard. / Histologic evidence of a radiosensitizing effect of Taxol in patients with astrocytomas. In: Journal of neuro-oncology. 1998 ; Vol. 39, No. 3. pp. 245-251.
@article{5274fdade9e645298924a504875add1f,
title = "Histologic evidence of a radiosensitizing effect of Taxol in patients with astrocytomas",
abstract = "The new anticancer agent Taxol appears to potentiate the effects of radiation on brain tumor cell lines in vitro and was recently evaluated by our group as a radiosensitizer in a phase I study for primary brain tumors. In that study, we administered Taxol as a three-hour IV infusion repeated every week for six weeks and gave daily cranial irradiation concurrently for a total of 6000 rads. We reviewed the charts of the 60 patients who participated in the study, and identified twelve patients who underwent a second surgery after treatment because of progressive symptoms and an enlarging intracranial mass on MRI. Pathologically, each patient showed prominent radionecrosis, and other evidence of accelerated radiation changes (confluent areas of coagulative necrosis, bizarre nuclei, marked thickening and fibrinoid changes in multiple blood vessels). These changes were noted many weeks earlier than would be expected after radiation therapy alone and were independent of age, and tumor histology. We postulate that the accelerated radiation changes may be due to the radiation sensitizing effects of Taxol. We also noted a change of the pattern of tumor recurrence, compared to historic reports, and a dose-necrosis relationship where the resected tumor is formed completely of necrotic tissue in patients who received 150 mg/m2 or higher dose of Taxol. These observations may be of significance for future study design.",
author = "Tarek Wehbe and Michael Glantz and Hak Choy and Lisa Glantz and Selina Cortez and Wallace Akerley and Pam Mills and Bernard Cole",
year = "1998",
month = "11",
day = "3",
doi = "10.1023/A:1005710710418",
language = "English (US)",
volume = "39",
pages = "245--251",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Wehbe, T, Glantz, M, Choy, H, Glantz, L, Cortez, S, Akerley, W, Mills, P & Cole, B 1998, 'Histologic evidence of a radiosensitizing effect of Taxol in patients with astrocytomas', Journal of neuro-oncology, vol. 39, no. 3, pp. 245-251. https://doi.org/10.1023/A:1005710710418

Histologic evidence of a radiosensitizing effect of Taxol in patients with astrocytomas. / Wehbe, Tarek; Glantz, Michael; Choy, Hak; Glantz, Lisa; Cortez, Selina; Akerley, Wallace; Mills, Pam; Cole, Bernard.

In: Journal of neuro-oncology, Vol. 39, No. 3, 03.11.1998, p. 245-251.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Histologic evidence of a radiosensitizing effect of Taxol in patients with astrocytomas

AU - Wehbe, Tarek

AU - Glantz, Michael

AU - Choy, Hak

AU - Glantz, Lisa

AU - Cortez, Selina

AU - Akerley, Wallace

AU - Mills, Pam

AU - Cole, Bernard

PY - 1998/11/3

Y1 - 1998/11/3

N2 - The new anticancer agent Taxol appears to potentiate the effects of radiation on brain tumor cell lines in vitro and was recently evaluated by our group as a radiosensitizer in a phase I study for primary brain tumors. In that study, we administered Taxol as a three-hour IV infusion repeated every week for six weeks and gave daily cranial irradiation concurrently for a total of 6000 rads. We reviewed the charts of the 60 patients who participated in the study, and identified twelve patients who underwent a second surgery after treatment because of progressive symptoms and an enlarging intracranial mass on MRI. Pathologically, each patient showed prominent radionecrosis, and other evidence of accelerated radiation changes (confluent areas of coagulative necrosis, bizarre nuclei, marked thickening and fibrinoid changes in multiple blood vessels). These changes were noted many weeks earlier than would be expected after radiation therapy alone and were independent of age, and tumor histology. We postulate that the accelerated radiation changes may be due to the radiation sensitizing effects of Taxol. We also noted a change of the pattern of tumor recurrence, compared to historic reports, and a dose-necrosis relationship where the resected tumor is formed completely of necrotic tissue in patients who received 150 mg/m2 or higher dose of Taxol. These observations may be of significance for future study design.

AB - The new anticancer agent Taxol appears to potentiate the effects of radiation on brain tumor cell lines in vitro and was recently evaluated by our group as a radiosensitizer in a phase I study for primary brain tumors. In that study, we administered Taxol as a three-hour IV infusion repeated every week for six weeks and gave daily cranial irradiation concurrently for a total of 6000 rads. We reviewed the charts of the 60 patients who participated in the study, and identified twelve patients who underwent a second surgery after treatment because of progressive symptoms and an enlarging intracranial mass on MRI. Pathologically, each patient showed prominent radionecrosis, and other evidence of accelerated radiation changes (confluent areas of coagulative necrosis, bizarre nuclei, marked thickening and fibrinoid changes in multiple blood vessels). These changes were noted many weeks earlier than would be expected after radiation therapy alone and were independent of age, and tumor histology. We postulate that the accelerated radiation changes may be due to the radiation sensitizing effects of Taxol. We also noted a change of the pattern of tumor recurrence, compared to historic reports, and a dose-necrosis relationship where the resected tumor is formed completely of necrotic tissue in patients who received 150 mg/m2 or higher dose of Taxol. These observations may be of significance for future study design.

UR - http://www.scopus.com/inward/record.url?scp=0031757384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031757384&partnerID=8YFLogxK

U2 - 10.1023/A:1005710710418

DO - 10.1023/A:1005710710418

M3 - Article

C2 - 9821110

AN - SCOPUS:0031757384

VL - 39

SP - 245

EP - 251

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -